Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of subcutaneous B007 for pemphigus
CTR20240985Phase 3Completed
- Sponsor
- SPH Cross-linked
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of B007 in pemphigus, sponsored by SPH Cross-linked. Started Jul 2024; status: completed.
02
Drugs
B007
03
Conditions
pemphigus
Beyond the preview
Go deeper on CTR20240985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240985.